In the BioHarmony Drug Report Database
Voretigene neparvovec
Luxturna (voretigene neparvovec) is a gene pharmaceutical. Voretigene neparvovec was first approved as Luxturna on 2018-11-22. It has been approved in Europe to treat leber congenital amaurosis and retinitis pigmentosa.
Trade Name
|
Luxturna |
|---|---|
Common Name
|
voretigene neparvovec |
ChEMBL ID
|
CHEMBL3707275 |
Indication
|
leber congenital amaurosis, retinitis pigmentosa |
Drug Class
|
Image (chem structure or protein)
